LONDON, January 28 /PRNewswire/ -- Immune Targeting Systems (ITS) Limited, a company developing synthetic vaccines for mutating viruses, today announced it has received GBP2.4m of investment as the second tranche of its series-A funding round. ITS's investors HealthCap, the London Technology Fund, Novartis Venture Fund & Truffle Capital provided additional funding to enable a seamless transition into the clinic for the company's universal flu vaccine program which has now entered the GMP pre-clinical phase.
Simultaneously ITS has moved to strengthen its board and management team with the appointment of Brenda Reynolds, a co-founder of PowderMed (acquired by Pfizer in 2006), as company director. Another seasoned vaccine industry professional, Jill Makin, former VP of R&D for Emergent Biosolutions and Microscience, also joins in a consultancy capacity and is responsible for the GMP vaccine manufacture and its release to the clinic.
ITS CEO Carlton Brown commented: "Brenda and Jill are valuable additions to the team and will help drive both our clinical and commercial programs forward. The second tranche of investment brings our total funding to more than GBP5m, including a GBP0.5m development grant from the London Development Agency. We are aiming to raise series-B investment in 2009 to fund our universal influenza vaccine clinical program to proof-of-concept and bring other prioritized candidates through the pipeline. We expect to commence the clinical program by the end of 2009. Despite the current economic climate, our research tells us that the market remains strong for both a successful universal influenza vaccine and therapeutic T-cell vaccine platform."
Corporate Inquiries Carlton Brown; Chief Executive Officer Tel +44-7970-944-454, +44-20-7691-4908 Email: email@example.com
|SOURCE Immune Targeting Systems (ITS) Limited|
Copyright©2009 PR Newswire.
All rights reserved